GI, endocrine & cardiovascular
Peptide hormones and medicines spanning gastrointestinal, endocrine, renal, and cardiovascular systems.
Questions
What does the GI, endocrine and cardiovascular category cover?
The sampled monographs include octreotide for endocrine and gastrointestinal conditions, linaclotide for constipation disorders, angiotensin II and terlipressin for high-acuity circulatory conditions, and investigational apraglutide for short bowel syndrome. This is a navigation group, not a shared-mechanism claim.
Are all sampled GI, endocrine and cardiovascular entries approved medicines?
No. Octreotide, linaclotide, angiotensin II, and terlipressin have documented approvals for specific indications and jurisdictions. Apraglutide remains investigational and has orphan designations rather than marketing approval. See each monograph's development table for the precise current status.
What kinds of evidence support the sampled entries in this group?
Octreotide's monograph cites established labeled uses and the PROMID study for midgut neuroendocrine tumors. Linaclotide has controlled evidence in constipation disorders. Angiotensin II and terlipressin have pivotal high-acuity trials, while apraglutide remains in clinical development. Evidence must be read by indication, not category.
Why should jurisdiction be checked carefully for terlipressin?
Terlipressin's documented indications differ across jurisdictions: its US approval is for hepatorenal syndrome type 1, while European and UK records include variceal bleeding, with European hepatorenal-syndrome status varying by country. The monograph's development table preserves those distinctions.
How should apraglutide be compared with approved entries in this category?
Apraglutide should be described as investigational, with phase 3 and extension studies and no established or recommended human dose. That status differs fundamentally from the defined labeled uses of octreotide, linaclotide, angiotensin II, and terlipressin.
Join the atlas. Get the evidence updates.
Receive concise notes when peptide evidence, status, or source records change.